Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody

Additional Information:
C100P: Casirivimab Biosimilar, SARS-CoV-2 Spike Monoclonal Antibody Recombinant Human IgG1 Kap|Human IgG1 kap|The anti-SARS-CoV-2 spike monoclonal antibody casirivimab biosimilar was produced in the casirivimab biosimilar CHO cells. |Specificity/Sensitivity: The casirivimab biosimilar specifically binds to the spike protein of SARS-CoV-2. |Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological |0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives. |Purity: >95% by SDS-|The research grade casirivimab biosimilar is shipped with ice |Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |Background What is casirivimab biosimilar research grade? Casirivimab is a human monoclonal antibody directed against the spike protein of SARS-CoV-2. Casirivimab is a human monoclonal antibody (IgG1κ isotype). Casirivimab biosimilar uses the same protein sequences as the therapeutic antibody casirivimab. Casirivimab/imdevimab is a combination medicine used for the treatment and prevention of COVID-19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. Casirivimab and imdevimab bind distinct epitopes on the RBD with dissoc constants KD of 46 and 47 pM, respectively. Please contact us if you are interested in the anti-SARS-CoV-2 spike monoclonal antibody imdevimab biosimilar. Syd Labs also provides the following research grade anti-SARS-CoV-2 spike antibody biosimilar proteins: Sotrovimab biosimilar, research grade, SARS-CoV-2 spike monoclonal antibody